Stable coronary heart disease: diagnosis and treatment

DOI: https://doi.org/10.29296/25877305-2018-12-09
Download full text PDF
Issue: 
12
Year: 
2018

Professor M. Glezer, MD I.M. Sechenov First Moscow State Medical University (Sechenov University)

The first clinical manifestation of coronary heart disease (CHD) is often angina pectoris in women and myocardial infarction in men. The paper gives an algorithm for the diagnosis and treatment in stable CHD.
Keywords: 
cardiology
therapy
coronary heart disease
angina pectoris

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Rekomendatsii po lecheniju stabil'noj ishemicheskoj bolezni serdtsa Evropejskogo obschestva kardiologov, 2013. Adaptirovannyj perevod // Ros. kardiol. zhurn. – 2014; 7: 7–79.
  2. Sekiya M., Sato M., Funada J. et al. Effects of the long-term administration of nicorandil on vascular endothelial function and the progression of arteriosclerosis // J. Cardiovasc. Pharmacol. – 2005; 46 (1): 63–7.
  3. Zhu W., Shan Y., Guo J. et al. Double-blind, multicenter active-controlled, randomized clinical trial to assess the safety and efficacy of orally administered nicorandil in patients with stable angina pectoris in China // Circ. J. – 2007; 71 (6): 826–33.
  4. The IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial // Lancet. – 2002; 359: 1269–75.
  5. Horinaka S., Yabe A., Yagi H. et al. Effects of nicorandil on cardiovascular events in patients with coronary artery disease in the Japanese Coronary Artery Disease (JCAD) study // Circ. J. – 2010; 74 (3): 503–9.
  6. Sakata Y., Nakatani D., Shimizu M. et al. Oral treatment with nicorandil at discharge is associated with reduced mortality after acute myocardial infarction // J. Cardiol. – 2012; 59 (1): 14–21.
  7. Bulahova E.Ju., Korennova O.Ju., Kondrasheva M.N. i dr. Klinicheskie preimuschestva terapii nikorandilom v sravnenii s izosorbid-5-mononitratom u bol'nyh IBS // Serdtse. – 2013; 2 (70): 83–7.